BofA upgrades Abbvie stock rating on immunology strength By Investing.com

BofA Securities upgraded AbbVie to Buy from Neutral and lifted its price target to $234 from $226, citing a strong Q1 beat, raised full-year 2026 guidance, and durable growth from Skyrizi and Rinvoq. AbbVie reported adjusted EPS of $2.65 versus $2.59 expected and revenue of $15.0B, $300M above consensus, while BofA sees limited competitive erosion and attractive long-term growth. The stock fell in pre-market trading despite the positive results, and Goldman Sachs also raised its target to $244 while keeping a Neutral rating.

Analysis

The market is treating this as a simple headline about a pipeline winner, but the bigger signal is that large-cap pharma growth is re-accelerating in a way that makes “quality defensives” look less bond-like and more like long-duration growth. That matters because it re-rates the entire immunology cohort: if one of the largest incumbents can credibly extend its growth runway deep into the next decade, then investors will likely assign higher terminal values to adjacent franchises with similar durability, especially those with cleaner patent runways and less capex intensity.

The second-order effect is on competitors and capital allocation, not just on ABBV itself. A sustained positive read-through on category expansion should pressure investors to rotate away from ex-growth pharma names and into companies with either faster pipeline conversion or better reinvestment optionality; by contrast, names relying on price/volume compression assumptions will likely see estimate risk over the next 2-4 quarters. The valuation setup is also tricky: when a stock screens optically cheap on earnings power but carries a high multiple because the market is capitalizing a long runway, the near-term upside depends on confidence in guidance, not on the current quarter.

The main risk is that the market is anchoring on peak optimism while ignoring how quickly sentiment can turn if forward prescription trends decelerate even modestly. Over the next 1-3 quarters, any evidence that the growth bridge beyond the current blockbuster duo is thinner than advertised would compress the multiple faster than earnings can rescue it. On the other hand, if management continues to beat and raise while peers show pipeline noise, the stock can keep working despite seeming expensive today because the real catalyst is estimate revision, not multiple expansion.

Consensus appears to be underestimating how powerful a widening gap between company expectations and street forecasts can be when the asset is already a core institutional holding. That creates a favorable setup for momentum-following flows over the next 30-90 days, but also makes the name vulnerable to sharp de-risking on any guidance hiccup. In short: the move is probably underdone if the company can sustain this cadence, but the margin of safety is thinner than the bullish commentary suggests.

Key Decisions for Investors

• Add to ABBV on pullbacks over the next 1-3 weeks; prefer staggered entry because the stock can gap on guidance revisions, but the risk/reward remains favorable if forward prescription trends stay intact.
• Pair long ABBV vs short a weaker-immunology peer basket over 1-3 months; thesis is that the market will reward credible duration and penalize names with more fragile growth bridges.
• Buy ABBV call spreads 2-4 months out, funded by selling higher strikes, to express upside from continued estimate revisions while limiting downside if the market fades the rerating.
• Reduce exposure to any pharma names whose valuation depends on terminal growth assumptions but lack visible product-cycle support; the relative trade should work if investors reprice durability premiums across healthcare.
• If ABBV fails to confirm follow-through in the next earnings cycle, cut the position quickly; the stock’s setup is more sensitive to guidance credibility than to current-quarter beats.